2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review

AJ Camm, GV Naccarelli, S Mittal, HJGM Crijns… - Journal of the American …, 2022 - jacc.org
The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a
substantial burden on patients and health care services. Although the management of AF …

Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial

DL Packer, JP Piccini, KH Monahan, HR Al-Khalidi… - Circulation, 2021 - Am Heart Assoc
Background: In patients with heart failure and atrial fibrillation (AF), several clinical trials
have reported improved outcomes, including freedom from AF recurrence, quality of life, and …

The impact of obesity on the cardiovascular system

I Csige, D Ujvárosy, Z Szabó, I Lőrincz… - Journal of diabetes …, 2018 - Wiley Online Library
Obesity is a growing health problem worldwide. It is associated with an increased
cardiovascular risk on the one hand of obesity itself and on the other hand of associated …

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

H Calkins, G Hindricks, R Cappato, YH Kim… - Ep …, 2018 - academic.oup.com
AFL atrial flutter AH arterial hypertension ANS autonomic nervous system APD action
potential duration ARREST-AF Aggressive Risk Factor Reduction Study for Atrial Fibrillation …

[PDF][PDF] 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

M Roffi, C Patrono, JP Collet, C Mueller… - Polish Heart …, 2015 - journals.viamedica.pl
5. Leczenie.............................................................. 1225 5.1. Farmakoterapia
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …

JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias

K Ono, Y Iwasaki, M Akao, T Ikeda, K Ishii… - Circulation …, 2022 - jstage.jst.go.jp
The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

A Goette, JM Kalman, L Aguinaga, J Akar… - Ep …, 2016 - academic.oup.com
The atria provide an important contribution to cardiac function. 1, 2 Besides their impact on
ventricular filling, they serve as a volume reservoir, host pacemaker cells and important parts …

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

H Heidbuchel, P Verhamme, M Alings, M Antz… - Ep …, 2015 - academic.oup.com
The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

[PDF][PDF] 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

PM Elliott, A Anastasakis, MA Borger… - Polish Heart …, 2014 - journals.viamedica.pl
Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …